Vanguard Asset Management’s Stoke Therapeutics STOK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$777K Buy
29,896
+4,782
+19% +$144K ﹤0.01% 1981
2026
Q2
$822K Hold
25,114
– – ﹤0.01% 1984
2026
Q1
$818K Buy
+25,114
New +$824K ﹤0.01% 1881

Other funds holding STOK

Vanguard Asset Management's STOK Position: Q3 2026 in Review

Vanguard Asset Management increased its Stoke Therapeutics (STOK) stake by 19% in Q3 2026, buying an estimated $144K and bringing the position to 29,896 shares worth $777K. The position accounts for ﹤0.01% of the portfolio, ranked #1981.

Vanguard Asset Management first reported a position in STOK in Q1 2026 and has held it in 3 quarters since. The position peaked at $822K in Q2 2026. 185 funds tracked by Wall St. Rank hold STOK as of Q3 2026.

  • Vanguard Asset Management held 29,896 shares of Stoke Therapeutics worth $777K as of Q3 2026.
  • Vanguard Asset Management bought 4,782 Stoke Therapeutics shares in Q3 2026, an estimated $144K.
  • Stoke Therapeutics made up ﹤0.01% of Vanguard Asset Management's portfolio in Q3 2026, its #1981 holding.
  • Vanguard Asset Management first reported a position in Stoke Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Asset Management's Stoke Therapeutics position peaked at $822K in Q2 2026.
  • 185 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q3 2026.

Based on Vanguard Asset Management's 13F filing for Q3 2026, filed 13 Nov 2026.